PFE vs RTX: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and RTX Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-05.
Pfizer Inc. Β· Healthcare
$26.33
+35.4% upside to fair value
Grade B
VS
RTX Corporation Β· Industrials
$172.90
-21.3% upside to fair value
Grade D
QuantHub Verdict
PFE has more upside to fair value (+35.4%). PFE trades at a lower forward P/E (19.3x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric PFE RTX
Current Price $26.33 $172.90
Fair Value Estimate $35.65 $136.05
Upside to Fair Value +35.4% -21.3%
Market Cap $149.8B $232.8B
Forward P/E 19.3x 32.1x
EV / EBITDA 12.9x 19.2x
Price / Sales 2.4x 2.6x
Price / FCF 16.5x 27.9x
Revenue Growth YoY -1.2% +8.7%
Gross Margin 70.3% 20.2%
Operating Margin 24.7% 10.4%
Return on Equity 8.7% 11.2%
Dividend Yield 0% 0%
FCF Yield 6.06% 3.59%
Analyst Consensus Hold Buy
Investment Thesis
PFE β€” Pfizer Inc.
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
RTX β€” RTX Corporation
RTX Corporation is a leading aerospace and defense company with a diversified portfolio spanning Pratt & Whitney jet engines, Collins Aerospace avionics, and Raytheon Intelligence & Space defense systems. The company benefits from a strong competitive moat supported by a $271 billion backlog and multi-year contracts, driving consistent revenue growth of 10% in 2025 and 9% in Q1 2026. Earnings gro…
Accumulation Zones
Metric PFE RTX
Zone Low $26.74 $102.04
Zone High $30.30 $115.64
In Buy Zone? Yes No
← PFE Research    RTX Research β†’    All Research